News for '-daiichi'

Ranbaxy promoters bring cos on Religare platform

Ranbaxy promoters bring cos on Religare platform

Rediff.com19 Sep 2008

The group's testing lab chain SRL Ranbaxy has been renamed as Religare Super Laboratories. RanAir, its charter aviation company will be known as Religare Voyages. About 15 group companies, including joint ventures like Religare Macquarie Private Wealth, Religare Aegon and Vistaar Religare have come under the umbrella brand Religare.

Peace on patents to boost Ranbaxy

Peace on patents to boost Ranbaxy

Rediff.com27 Aug 2008

Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US.

Sun-Ranbaxy merger clears last hurdle

Sun-Ranbaxy merger clears last hurdle

Rediff.com10 Mar 2015

On January 31, the US Federal Trade Commission cleared the merger.

Advani snubs Ranbaxy deal

Advani snubs Ranbaxy deal

Rediff.com23 Jun 2008

Profit motives shouldn't override national interests, said BJP leader at the Business Standard annual awards function. Though he did not name Ranbaxy, the signal from the Bharatiya Janata Party's prime ministerial candidate was clear.

HC lifts stay on Sun Pharma's $3.2 billion Ranbaxy takeover

HC lifts stay on Sun Pharma's $3.2 billion Ranbaxy takeover

Rediff.com24 May 2014

Both companies can now complete the deal.

Sun Pharma makes open offer for Zenotech stake

Sun Pharma makes open offer for Zenotech stake

Rediff.com13 Apr 2014

Sun Pharma has evinced its interest in buying Hyderabad-based biotech company Zenotech Laboratories, through an open offer to buy 28.1 per cent worth Rs 18.41 crore ($3 million).

Malvinder Singh on Ranbaxy's setback

Malvinder Singh on Ranbaxy's setback

Rediff.com17 Jul 2008

All medicines that have USFDA approvals continue to be produced in the Poanta Sahib facility. The USFDA has not given any approval for new drugs as they have some concerns. We are addressing them, Malvinder Singh said.

Ranbaxy resets FCCB price 39 per cent

Ranbaxy resets FCCB price 39 per cent

Rediff.com28 Oct 2008

The price has been cut 39 per cent to Rs 555.85 from Rs 908 per share originally after its request to redeem the bonds ahead of maturity was rejected by the Reserve Bank of India.

Ranbaxy buy in line with Sun's strategy

Ranbaxy buy in line with Sun's strategy

Rediff.com17 Apr 2014

The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.

Malvinder gets hefty hike from new owners

Malvinder gets hefty hike from new owners

Rediff.com21 Jun 2008

Promoter of Ranbaxy Laboratories, Malvinder Mohan Singh, not only sold a strategic stake in his company to Japanese pharma major Daiichi Sankyoand, he even managed to get a good increment for himself. According to the company's extraordinary general meeting notice, Singh will now earn a salary and allowances of Rs 25 crore per annum as against Rs 19.58 crore earlier.

Sun gets US trade regulator nod for Ranbaxy merger

Sun gets US trade regulator nod for Ranbaxy merger

Rediff.com1 Feb 2015

Torrent to buy Ranbaxy's anti-bacterial generic

Fortis shareholders vote out director, shadow over sale

Fortis shareholders vote out director, shadow over sale

Rediff.com23 May 2018

Brian Tempest is among the four directors of cash-strapped healthcare chain whose removals were sought by two institutional investors. Three directors -- Harpal Singh, Sabina Vaisoha and Tejinder Singh Shergill -- had already resigned before the EGM.

GST compensation row: FM's 'act of God' can be a nightmare for RBI

GST compensation row: FM's 'act of God' can be a nightmare for RBI

Rediff.com7 Sep 2020

The central bank is the money manager of the government, and not a guarantor of any debt.

How Malvinder and Shivinder Singh destroyed the legacy they inherited

How Malvinder and Shivinder Singh destroyed the legacy they inherited

Rediff.com27 Mar 2018

Over-expansion, bad management, and multiple allegations irreparably taint Malvinder and Shivinder Singh

Ranbaxy staff get pay-cut shield in Sun buyout

Ranbaxy staff get pay-cut shield in Sun buyout

Rediff.com20 Oct 2014

Sun maintained it would retain the best of both organisations to build a global pharma company.

Rupee gains for 2nd session; up 3 paise against dollar

Rupee gains for 2nd session; up 3 paise against dollar

Rediff.com22 Apr 2015

The rupee on Wednesday strengthened by another 3 paise to 62.82 against the US dollar.

United Spirits, Vijay Mallya set for a lengthy legal battle

United Spirits, Vijay Mallya set for a lengthy legal battle

Rediff.com27 Apr 2015

USL is already contesting a Karnataka High Court order.

Tsunami hits Japan after strong 6.9 quake

Tsunami hits Japan after strong 6.9 quake

Rediff.com22 Nov 2016

The quake struck on Tuesday morning at about 06:00 local time (2:30 am IST on Tuesday), the Japan Meteorological Agency said, adding that the epicentre of the quake, which was felt in Tokyo, was off the coast of Fukushima prefecture at a depth of about 25km, the agency said.

40 years ago and now: How Ranbaxy moved out of family control

40 years ago and now: How Ranbaxy moved out of family control

Rediff.com22 Oct 2014

Ranbaxy did its maiden public issue in 1973.

Rupee recovers from 3-month low; up 6 paise against dollar

Rupee recovers from 3-month low; up 6 paise against dollar

Rediff.com21 Apr 2015

The rupee recovered from more-than three months low of 63.15 in early trade on dollar selling by banks.

Court orders temporary halt on Sun Pharma's takeover of Ranbaxy

Court orders temporary halt on Sun Pharma's takeover of Ranbaxy

Rediff.com1 May 2014

Two individuals filed the petition in the high court of Andhra Pradesh

Fortis' Shivinder Singh to step down; to join spiritual organisation

Fortis' Shivinder Singh to step down; to join spiritual organisation

Rediff.com23 Sep 2015

Fortis Healthcare Executive Vice-Chairman Shivinder Mohan Singh is stepping down from his position to join a philosophical and spiritual organisation.

Indian regulator also scans Ranbaxy

Indian regulator also scans Ranbaxy

Rediff.com20 Sep 2013

The move comes in the wake of many facilities of Ranbaxy in India being barred by the US Food and Drugs Administration for supplying medicines to the US.

Another sibling war ensues! Shivinder sues elder brother Malvinder

Another sibling war ensues! Shivinder sues elder brother Malvinder

Rediff.com5 Sep 2018

"My family reputation kept me a silent spectator, as I mutely watched the organisation I founded come to a point where it was publicly auctioned; where my family and myself have been stripped of our legacy, our finances and my personal credibility."

USFDA raises concerns about Ranbaxy's Toansa plant

USFDA raises concerns about Ranbaxy's Toansa plant

Rediff.com13 Jan 2014

All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.

FDI in pharma doubled during April-August

FDI in pharma doubled during April-August

Rediff.com18 Nov 2013

FDI in drugs and pharmaceuticals was $487 million during April-August 2012, according to the latest data of the Department of Industrial Policy and Promotion.

Lessons from the Fortis/Raymond family feuds

Lessons from the Fortis/Raymond family feuds

Rediff.com7 Jan 2019

'Nothing in this world is permanent. So also in business.' 'And more so in family businesses where family issues often influence business decisions,' point out S Subramanian and Nupur Pavan Bang.

Before & After: Revisiting the moment that knocked the world off its axis

Before & After: Revisiting the moment that knocked the world off its axis

Rediff.com11 Mar 2016

On March 11, 2011, a magnitude 9.0 earthquake struck at 2:46 PM Japanese Standard Time off the coast of Japan, unleashing enough seismic force to knock the entire world off its axis by more than six inches. Five years later, here's is a comparative photo-feature showing how much things have changed since then

FIPB to take up 34 FDI proposals on May 13

FIPB to take up 34 FDI proposals on May 13

Rediff.com11 May 2014

SSTL is the second operator after Vodafone that has approached FIPB for raising FDI limit.

DON'T MISS! Best photos of the week

DON'T MISS! Best photos of the week

Rediff.com14 Nov 2014

We bring you a collection of some of the best photographs taken this week by ace Reuters photographers.

FIPB clears GlaxoSmithKline's Rs 6,400-crore FDI proposal

FIPB clears GlaxoSmithKline's Rs 6,400-crore FDI proposal

Rediff.com13 Jan 2014

The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.

2018: Year of reckoning for India Inc

2018: Year of reckoning for India Inc

Rediff.com28 Dec 2018

A glance back at some of the important ups and down Indian Inc faced in 2018.

Sun Pharma to delist Ranbaxy on completion of $4-bn merger

Sun Pharma to delist Ranbaxy on completion of $4-bn merger

Rediff.com25 Mar 2015

The merger has fortified Sun Pharma's position.

House panel for 'blanket ban' on FDI in pharma

House panel for 'blanket ban' on FDI in pharma

Rediff.com14 Aug 2013

The report comes at a time when the government is trying to clear pending FDI proposals, which include various planned investments in this sector.

Suspected human hair in tablet cited in Ranbaxy ban

Suspected human hair in tablet cited in Ranbaxy ban

Rediff.com18 Sep 2013

Ranbaxy, which is 63.5 per cent-owned by Japan's Daiichi Sankyo Co and gets more than 40 per cent of its sales from the United States, did not immediately respond to a request on Wednesday for comment on the FDA observations.

Sun-Ranbaxy deal stirs monopoly concerns: CCI

Sun-Ranbaxy deal stirs monopoly concerns: CCI

Rediff.com30 Aug 2014

Competition watchdog says 'high market concentration' in some segments a worry.

Indian bourses' nod for Sun Pharma-Ranbaxy deal

Indian bourses' nod for Sun Pharma-Ranbaxy deal

Rediff.com21 Jul 2014

The deal had separately come under scanner of the market regulator Sebi for alleged insider trading violations and the present 'no-objection' from the exchanges.

Profit might be hit in FY16: Sun Pharma

Profit might be hit in FY16: Sun Pharma

Rediff.com21 Jul 2015

4 Ranbaxy facilities in India have been barred from exporting to US.

Abe, Singh to meet today; investment deals likely

Abe, Singh to meet today; investment deals likely

Rediff.com25 Jan 2014

The annual summit between India and Japan on Saturday will seek to forge greater bilateral trade and investment ties, with Japanese Prime Minister Shinzo Abe coming with a high-powered business delegation.

No plans to reduce workforce: Ranbaxy

No plans to reduce workforce: Ranbaxy

Rediff.com2 Oct 2013

The company has been reported to be retrenching staff.